Trv Gp Iv, LLC Tango Therapeutics, Inc. Transaction History
Trv Gp Iv, LLC
- $162 Million
- Q3 2024
A detailed history of Trv Gp Iv, LLC transactions in Tango Therapeutics, Inc. stock. As of the latest transaction made, Trv Gp Iv, LLC holds 16,859,075 shares of TNGX stock, worth $49.4 Million. This represents 80.09% of its overall portfolio holdings.
Number of Shares
16,859,075
Previous 19,201,475
12.2%
Holding current value
$49.4 Million
Previous $165 Million
21.2%
% of portfolio
80.09%
Previous 81.48%
Shares
3 transactions
Others Institutions Holding TNGX
# of Institutions
121Shares Held
91.7MCall Options Held
3.1KPut Options Held
1.5K-
Eco R1 Capital, LLC San Francisco, CA13.3MShares$39.1 Million4.45% of portfolio
-
Boxer Capital, LLC San Diego, CA8.2MShares$24 Million3.35% of portfolio
-
Nextech Invest Ag5.53MShares$16.2 Million6.95% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD5.02MShares$14.7 Million0.02% of portfolio
-
Southpoint Capital Advisors LP New York, NY5MShares$14.7 Million1.08% of portfolio
About Tango Therapeutics, Inc.
- Ticker TNGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 88,067,296
- Market Cap $258M
- Description
- Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops...